Status:

COMPLETED

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Lead Sponsor:

Idorsia Pharmaceuticals Ltd.

Conditions:

Seasonal Allergic Rhinitis

Eligibility:

All Genders

12-76 years

Phase:

PHASE3

Brief Summary

This study will assess the efficacy and safety of ACT-129968 in adolescent, adult and elderly patients with seasonal allergic rhinitis, due to mountain cedar pollen.

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Males and females aged 12-76 years with documented clinical history of symptomatic seasonal allergic rhinitis associated with mountain cedar pollen for the last 2 years.
  • Evening reflective Total Nasal Symptom Score (p.m.rTNSS) at least 42 out of a maximum potential score of 84 over the 7-day run-in period, or \> or = 6 out of a maximum score of 12 on each of the last 4 consecutive days during the run-in period.
  • Exclusion Criteria
  • Non-allergic rhinitis.
  • Severe physical nasal obstruction.
  • Acute or significant chronic sinusitis.
  • Bacterial or viral infection of the upper or lower respiratory tract, nasal sinuses, or middle ear.
  • Ongoing chronic respiratory disorders.
  • Asthma requiring use of short-acting beta2-agonists \> 2 times a week or any asthma treatment other than inhaled short-acting beta2-agonists.
  • Diagnosis of aspirin or non-steroidal anti-inflammatory drug (NSAID)-induced asthma.
  • Nasal biopsy or surgery, sinus surgery, or perforation within the 8 weeks prior to the Screening Visit.
  • Ocular surgery within the 8 weeks prior to the Screening Visit.
  • Ocular infections (bacterial or viral) within the 4 weeks before screening.
  • Use of forbidden medications (prescribed or over-the-counter \[OTC\])
  • Congenital or acquired severe immunodeficiency or known Human immunodeficiency virus (HIV)infection.

Exclusion

    Key Trial Info

    Start Date :

    December 1 2011

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    March 1 2012

    Estimated Enrollment :

    630 Patients enrolled

    Trial Details

    Trial ID

    NCT01484119

    Start Date

    December 1 2011

    End Date

    March 1 2012

    Last Update

    September 28 2018

    Active Locations (7)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 2 (7 locations)

    1

    Clinical Investigative Site 7905

    Austin, Texas, United States, 78731

    2

    Clinical Investigative Site 7907

    Kerrville, Texas, United States, 78028

    3

    Clinical Investigative Site 7903

    New Braunfels, Texas, United States, 78130

    4

    Clinical Investigative Site 7901

    San Antonio, Texas, United States, 78229